Display search results for ** instead (452 products)
30 Jun 2014  |  North America
The Ideal Life Sciences Hub
There are a number of factors that influence a life sciences companys decision in selecting the perfect location for its research and development (R&D), manufacturing operations, or headquarters. This Vital Signs article discusses those factors and discusses why Carlsbad, California, is one ideal Life Sciences hub location. Case studies include I...
USD 187.50 save 25 %
21 Mar 2014  |  North America
In early November 2013, Frost & Sullivan conducted an online survey, followed up by a live focus group with about 20 C-suite executives from leading commercial payer organizations across the US. The goal was to gain insights into how the health insurance industry is approaching the use of analytics solutions going into 2014. Analytics solutions we...
07 Apr 2014  |  North America
Healthcare systems across the globe are facing rising operation costs, shortage of skilled labor and budgetary restraints, which has resulted in reduction in efficiency and quality of care. An increasing aging population, need for chronic disease management and providing access to healthcare for the geographically fragmented population demands the ...
19 Dec 2014  |  North America
As the Wearables sector continues to explode in interest in the healthcare space in terms of potential hard benefit to consumers, providers, and vendors across the value chain of connected healthcare, areas are expanding in launches besides that of activity tracking. The following Vital Signs presents analyst discussion regarding brain wearables in...
31 Mar 2014  |  North America
This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.
17 Jan 2014  |  North America
This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.
28 Feb 2014  |  North America
This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.
23 Sep 2014  |  North America
The wearables market is currently a center of hype and interest across the varied landscape of consumers, vendors, providers, payers, and other stakeholders interested in the broader digital health market. Companies are trying to better understand consumer habits, exploring device monetization outside of the early adopting fitness crowd, increasing...
03 Oct 2014  |  North America
Electronic cigarettes and vaping products have taken the tobacco industry by storm. Multiple public reports have e-cigarettes surpassing traditional tobacco sales within the next six to ten years if growth rates continue to climb. Due to the lack of Food and Drug Administration (FDA) regulation, e-cigarette year-over-year growth declined from 2010-...
06 Apr 2014  |  North America
Evolving Customer Demands Spurring Competitive Dynamics
Ongoing technology and clinical advances in every imaging modality continue to bring advanced visualization (AV) and clinical applications to centerstage. AV is not just a core step in the interpretation workflow of each of these modalities, but essentially the set of solutions that allows to realize the promises of the advances on the equipment si...